Inovio Pharmaceuticals Inc expected to post a loss of 84 cents a share - Earnings Preview

Inovio Pharmaceuticals

28/02/2025 21:02

Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to show a fall in quarterly revenue when it reports  results on March 4 (estimated) for the period ending December 31 2024

The Plymouth Meeting Pennsylvania-based  company is expected to report a 70.8% decrease in revenue to $30 thousand from $102.65 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of 84 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $8.00​, above​ its last closing price of $1.94. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.14
-1.15
-0.89
Beat
22.6
Jun. 30 2024
-1.12
-1.10
-1.19
Missed
-8
Mar. 31 2024
-1.01
-1.00
-1.31
Missed
-30.6​
Dec. 31 2023
-1.42
-1.27
-1.12
Beat
11.6
​​Sep. 30 2023
-1.50
-1.52
-1.56
Missed
-2.6
Jun. 30 2023
-1.81
-1.74
-1.56
Beat
10.3​
Mar. 31 2023
-1.76
-1.74
-1.92
Missed
-10.3
Dec. 31 2022
-2.01
-2.02
-2.52
Missed
-25

This summary was machine generated February 28 at 21:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)